Zobrazeno 1 - 10
of 24
pro vyhledávání: '"785"'
Publikováno v:
Blood. 120:3789-3789
Abstract 3789 Introduction: Recently, genes affecting the splicing machinery have been found to be frequently mutated in MDS patients. The U2AF1 gene codes for one of these splicing components, showing two distinct mutational hot spots at amino acids
Publikováno v:
Blood. 132:4849-4849
Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly used low intensity regimens are azacitidine (AZA), decitabine (DEC), or low-dose cytarabine
Autor:
Anja Mottok, Christian Steidl, Randy D. Gascoyne, Maryse M. Power, David Scott, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Sohrab P. Shah, Joseph M. Connors
Publikováno v:
Blood. 124:136-136
Introduction : Classical Hodgkin lymphoma (cHL) is the most common lymphoma affecting individuals under the age of 30. Despite improvements in standard treatment, 25-30% of patients still relapse after first-line treatment with ABVD. Relapsed patient
Autor:
Tammy T. Hshieh, Robert J. Soiffer, Chelsea E. Hawley, Clark DuMontier, Richard Stone, Gregory A. Abel, Jane A. Driver, Tim Jaung, Nupur E. Bahl, Emily S. Magnavita, Lee Mozessohn
Publikováno v:
Blood. 138:4089-4089
Background. Polypharmacy and potentially inappropriate medications (PIMs) are common among older adults with blood cancer and can lead to adverse effects and poor outcomes. Polypharmacy is commonly defined as taking ≥5 or ≥8 medications, dependin
Autor:
Colin Burke O'Leary, Megha Shalavadi, Timothy S. Oh, Aryeh Pelcovits, Frederick Lansigan, Jason Lofters, Adam J. Olszewski, Reem Karmali, Elaine Kuhn, Jean L. Koff, Andrew M. Evens, Neil Palmisiano, Melissa Kives, Mingen Liu, Ning C. Dong, Andrea Anampa-Guzman, Tatyana Feldman, Nadia Khan, Stefan K. Barta, Alexey V. Danilov, Jordan Carter, Kerry J. Savage, Shazia Nakohda, Colin Thomas, Carman Tong, Francisco J. Hernandez-Ilizaliturri, Kittika Poonsombudlert, Sabarish Ayyappan, Alexander Hershey, Matthew A. Lunning
Publikováno v:
Blood. 138:50-50
Introduction: While an association between AI diseases and the development of lymphoma (LYM) is known, the impact of AI diseases on patient (pt) outcome across varying LYM subtypes, including the role of immunosuppressive medications (ISM), is not we
Autor:
Christoph Tinchon, Wolfgang R. Sperr, Manuel Drost, Sonja Vallet, Sonja Heibl, Branka Petricevic, Alexander Egle, Hubert Angermann, Gudrun Piringer, Dominik Wolf, Richard Greil, Armin Zebisch, Michael Pfeilstöcker, Heinz Sill, Andreas L. Petzer, Bernd L. Hartmann, Clemens A. Schmitt, Klaus Geissler, Lisa Pleyer, Julian Larcher-Senn, Thomas Melchardt, Margarete Stampfl-Mattesberger, Michael Girschikofsky, Reinhard Stauder, Michael Leisch, Felix Keil, Sigrid Machherndl-Spandl
Publikováno v:
Blood. 138:3387-3387
Background In myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) achievement of complete remission (CR) is a prerequisite for potential cure. In AML, CR/CR with incomplete recovery (CRi) is deemed
Autor:
Oliver Meier, Martynas Aizenas, Francis Nissen, Paul McLaughlin, Cédric Hermans, Thomas W. Burke, Harpal Dhillon, Jamie O'Hara, Sohaib Asghar
Publikováno v:
Blood. 136:33-34
Introduction Severe hemophilia A (SHA) is characterized by spontaneous (non-trauma related) bleeding episodes into the joint space and muscle tissue, leading to progressive joint deterioration and chronic pain. Chronic joint damage is most often asso
Publikováno v:
Blood. 136:21-22
Introduction Chimeric Antigen Receptor (CAR) T cell therapy has improved outcomes for relapsed and/or refractory (r/r) B cell lymphomas. Bridging therapy might be needed in some patients for disease control while CAR T product is being produced. Radi
Publikováno v:
Blood. 134:3635-3635
Introduction: Replacement factor VIII (FVIII) products have been administered to achieve desired FVIII levels for bleed treatment, perioperative management, or routine prophylaxis. Individual variability in pharmacokinetics (PK) has resulted in dosin
Autor:
Natia Esiashvili, Pamela B. Allen, Mohammad K. Khan, Mary Jo Lechowicz, Christopher R. Flowers, Matthew R Kudelka
Publikováno v:
Blood. 132:1639-1639
Introduction: Total skin electron beam (TSEB) therapy is a well-established treatment modality for patients suffering from cutaneous T-cell lymphoma (CTCL). It is often augmented with maintenance therapy, including skin directed and systemic therapie